A Phase 3 Molluscum Contagiosum Efficacy and Safety Study
Status:
Completed
Trial end date:
2021-07-28
Target enrollment:
Participant gender:
Summary
This is a phase 3 multi-center, randomized, double-blind, vehicle-controlled, parallel group
study to be conducted in up to approximately 850 subjects 6 months of age and older with
molluscum contagiosum (MC). Subjects or their caregivers will apply SB206 10.3% or Vehicle
Gel once daily for a minimum of 4 weeks and up to 12 weeks to all lesions identified at
Baseline and new treatable lesions that arise during the course of the study.